158 related articles for article (PubMed ID: 35404425)
21. FHR-5 Serum Levels and
Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
Front Immunol; 2021; 12():720183. PubMed ID: 34566977
[TBL] [Abstract][Full Text] [Related]
22. Membranoproliferative glomerulonephritis in Russian population.
Dobronravov VA; Smirnov AV
Ter Arkh; 2018 Dec; 90(12):39-47. PubMed ID: 30701832
[TBL] [Abstract][Full Text] [Related]
23. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.
Nakagawa N; Mizuno M; Kato S; Maruyama S; Sato H; Nakaya I; Sugiyama H; Fujimoto S; Miura K; Matsumura C; Gotoh Y; Suzuki H; Kuroki A; Yoshino A; Nakatani S; Hiromura K; Yamamoto R; Yokoyama H; Narita I; Isaka Y
PLoS One; 2021; 16(9):e0257397. PubMed ID: 34520493
[TBL] [Abstract][Full Text] [Related]
24. Membranoproliferative glomerulonephritis and circulating cryoglobulins.
Hiramatsu R; Hoshino J; Suwabe T; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Sawa N; Takaichi K; Ohashi K; Fujii T; Ubara Y
Clin Exp Nephrol; 2014 Feb; 18(1):88-94. PubMed ID: 23722669
[TBL] [Abstract][Full Text] [Related]
25. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
26. To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis.
Nayak PP; Pradhan P; Pradhan D; Mohapatra N; Raman S; Sahoo P
Indian J Pathol Microbiol; 2024; 67(1):80-85. PubMed ID: 38358193
[TBL] [Abstract][Full Text] [Related]
27. The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease.
Afolabi H; Zhang BM; O'Shaughnessy M; Chertow GM; Lafayette R; Charu V
Am J Kidney Dis; 2024 Jan; 83(1):79-89. PubMed ID: 37739026
[TBL] [Abstract][Full Text] [Related]
28. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
29. Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.
Meuleman MS; Vieira-Martins P; El Sissy C; Audard V; Baudouin V; Bertrand D; Bridoux F; Louillet F; Dossier C; Esnault V; Jourde-Chiche N; Karras A; Morin MP; Provot F; Remy P; Ribes D; Rousset-Rouviere C; Servais A; Thervet E; Tricot L; Zaidan M; Wynckel A; Zuber J; Le Quintrec M; Frémeaux-Bacchi V; Chauvet S
Clin J Am Soc Nephrol; 2023 Nov; 18(11):1435-1445. PubMed ID: 37615951
[TBL] [Abstract][Full Text] [Related]
30. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.
Little MA; Dupont P; Campbell E; Dorman A; Walshe JJ
Kidney Int; 2006 Feb; 69(3):504-11. PubMed ID: 16395262
[TBL] [Abstract][Full Text] [Related]
31. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
Khandelwal P; Bhardwaj S; Singh G; Sinha A; Hari P; Bagga A
Pediatr Nephrol; 2021 Mar; 36(3):591-600. PubMed ID: 32886193
[TBL] [Abstract][Full Text] [Related]
32. Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter study.
Woo SA; Young Ju H; Hyo Kwon S; Lee JH; Jeong Choi S; Cheol Han D; Duk Hwang S; Hong SY; Jin SY; Gil HW
Kidney Res Clin Pract; 2014 Dec; 33(4):187-91. PubMed ID: 26885475
[TBL] [Abstract][Full Text] [Related]
33. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
34. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
35. Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis.
Lomax-Browne HJ; Medjeral-Thomas NR; Barbour SJ; Gisby J; Han H; Bomback AS; Fervenza FC; Cairns TH; Szydlo R; Tan SJ; Marks SD; Waters AM; Appel GB; D'Agati VD; Sethi S; Nast CC; Bajema I; Alpers CE; Fogo AB; Licht C; Fakhouri F; Cattran DC; Peters JE; Cook HT; Pickering MC
Clin J Am Soc Nephrol; 2022 Jul; 17(7):994-1007. PubMed ID: 35777834
[TBL] [Abstract][Full Text] [Related]
36. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
37. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
38. Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study.
Honma S; Sato N; Sakaguchi R; Hashiguchi A; Uesugi N; Nakamura Y; Sasano H; Joh K
Med Mol Morphol; 2024 Mar; 57(1):23-34. PubMed ID: 37823929
[TBL] [Abstract][Full Text] [Related]
39. Recurrence of membranoproliferative glomerulonephritis post transplant - Is this mere recurrence of pattern or recurrence of disease?
Lingaraj U; Patil SR; Aralapuram K; Mallappa SS; Gurusiddaiah SC; Vankalakunti M
Saudi J Kidney Dis Transpl; 2019; 30(3):719-722. PubMed ID: 31249240
[TBL] [Abstract][Full Text] [Related]
40. Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection?
Andresdottir MB; Assmann KJ; Hilbrands LB; Wetzels JF
Am J Kidney Dis; 2000 Feb; 35(2):E6. PubMed ID: 10781414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
